Stratrix
Company data sheet · Boston Scientific

Boston Scientific: from profit to three straight losses.

Industry
Surgical & Medical Instruments & Apparatus
Headquarters
United States
Ticker
BSX (NYSE)
Sources
SEC filings (1995–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
Data as of
November 15, 2026
  1. From profit to three straight losses. Boston Scientific lost money every year from 2013 to 2015: $0.5 billion in all. 2016 was its first profit in four years: $0.3 billion.
  2. Leaders came and went. Boston Scientific filed 39 leadership changes since 2016, more than 91% of large manufacturers (the median is 20). The day after each, its shares fell a median 0.5 points against its sector.

Financial results

Fiscal yearRevenueNet income
2016$9.1 billion$0.3 billion
2017$9 billion$0.1 billion
2018$9.8 billion$1.7 billion
2019$10.7 billion$4.7 billion
2020$9.9 billion−$0.1 billion
2021$11.9 billion$1 billion
2022$12.7 billion$0.7 billion
2023$14.2 billion$1.6 billion
2024$16.7 billion$1.8 billion
2025$20.1 billion$2.9 billion

As reported in its annual filings. Losses in red.

Has Boston Scientific had layoffs?

Headcount, as reported

Annual reportEmployeesAs of
10-K for 2023approximately 48,000December 31, 2023
10-K for 2024approximately 53,000December 31, 2024
10-K for 2025approximately 59,000December 31, 2025

Job cuts, severance and restructuring

  1. Board approved a new global restructuring program, the 2023 Restructuring Plan, with expected limited role reductions and a total estimated pre-tax charge range. Cost: total pre-tax charges of approximately $450 million to $550 million

    “The 2023 Restructuring Plan is expected to result in 23 total pre-tax charges of approximately $450 million to $550 million and reduce gross annual pre-tax expenses by approximately $225 million to $275 million as program benefits are realized.” 10-K for 2023
  2. Company recorded restructuring charges under the 2023 Restructuring Plan, plus restructuring-related charges, in 2023. 2023

    “Pursuant to the 2023 Restructuring Plan, we recorded restructuring charges in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 420, Exit or Disposal Cost Obligations of $69 million in 2023.” 10-K for 2023
  3. Company expects termination benefits and other charges under the 2023 Restructuring Plan, with costs for employee-related actions estimated by type.

    “Termination benefits (1) $60 - $80 Other (2) 20 - 40 Restructuring-related expenses: Transfer costs (3) 300 - 330 Other (4) 70 - 100 $450 - $550 (1) Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.” 10-K for 2023
  4. Company reported cash outlays expected from the 2023 Restructuring Plan.

    “The implementation of the 2023 Restructuring Plan is estimated to result in total pre-tax charges of approximately $450 million to $550 million, of which approximately $350 million to $450 million is expected to result in cash outlays, and reduce gross annual pre-tax expenses by approximately $225 million to $275 million as program benefits are realized.” 10-K for 2023
  5. Company completed its 2019 Restructuring Plan, reporting its total charges and cash outlays, and recorded 2022 charges under it.

    “The 2019 Restructuring Plan resulted in total pre-tax charges of $461 million and approximately $404 million in cash outlays.” 10-K for 2023
  6. The company recorded restructuring charges and restructuring-related charges under the 2023 Restructuring Plan during 2024.

    “We recorded Restructuring net charges (credits) of $ 16 million in 2024, $ 69 million in 2023 and $ 24 million in 2022.” 10-K for 2024
  7. The company reported a restructuring reserve balance at year end, reflecting severance and other exit costs not yet paid. As of December 31, 2024

    “The restructuring reserve balance as of December 31, 2024 and 2023 was $ 26 million and $ 41 million, respectively.” 10-K for 2024
  8. The 2023 Restructuring Plan includes termination benefits for affected employees, with plans developed by region and business.

    “Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.” 10-K for 2024
  9. The company committed to a global restructuring program in February 2023 to simplify its manufacturing and distribution network and expand operating efficiencies. Cost: approximately $700 million to $800 million

    “The 2023 Restructuring Plan is expected to result in total pre-tax charges of approximately $700 million to $800 million and reduce gross annual pre-tax expenses by approximately $350 million to $400 million as program benefits are realized.” 10-K for 2025
  10. The Board approved expanding the 2023 Restructuring Plan with up to $250 million in additional pre-tax charges for further efficiency and functional optimization activities. On July 29, 2025 · Cost: up to $250 million

    “On July 29, 2025, our Board of Directors approved expanding the 2023 Restructuring Plan by up to $250 million in aggregate additional pre-tax charges, to include further related activities under the program to drive operational efficiencies and optimize functional capabilities.” 10-K for 2025
  11. The company discontinued worldwide sales of the ACURATE aortic valve systems and recorded restructuring charges as a result. Cost: approximately $87 million

    “The decision resulted in total pre-tax restructuring and restructuring-related net charges of approximately $87 million in 2025.” 10-K for 2025
Reported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedRestructuring chargesRestructuring costs incurredCash paid for restructuring
2016-12-31$28 million$78 million$82 million
2017-12-31$37 million$95 million$70 million
2018-12-31$36 million$96 million—
2019-12-31$38 million—$64 million
2020-12-31$52 million——
2021-12-31$40 million——
2022-12-31$24 million——
2023-12-31$69 million——
2024-12-31$16 million——
2025-12-31$101 million——

Boston Scientific filed 5 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.

What has Boston Scientific acquired?

Deals its annual reports describe

BusinessDealWhenValue
Apollo Endosurgery, Inc.
“In the second quarter of 2023, we completed the acquisition of Apollo Endosurgery, Inc., a public company that has developed and commercialized endoscopic suturing devices including OverStitch™ Endoscopic Suturing Systems and X-Tack™ Endoscopic HeliX Tacking Systems and endobariatric devices including the Apollo ESG™ and Apollo REVISE™ Systems, the first devices authorized by the FDA for endoscopic sleeve gastroplasty and endoscopic bariatric revision procedures, as well as the Orbera™ ® Intragastric Balloon for endoscopic weight management.” 10-K for 2023
acquisitionIn the second quarter of 2023—
Relievant Medsystems, Inc.
“In addition, in the fourth quarter of 2023, we completed the acquisition of Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept™ Intraosseous Nerve Ablation System, the only FDA-cleared system to treat vertebrogenic pain, a form of chronic low back pain.” 10-K for 2023
acquisitionIn the fourth quarter of 2023—
Acotec Scientific Holdings Limited (majority stake)
“In the first quarter of 2023, we acquired a majority stake investment in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases, complementing our existing Peripheral Interventions portfolio.” 10-K for 2023
acquisitionIn the first quarter of 2023—
Axonics, Inc.
“On January 8, 2024, we announced our entry into a definitive agreement to acquire Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction.” 10-K for 2023
agreed acquisition——
pathology business
“as well as the divestiture of our pathology business during the second quarter of 2023 and our acquisition of Baylis Medical Company Inc. (Baylis Medical) during the first quarter of 2022, for which there is less than a full period of comparable net sales.” 10-K for 2023
divestitureduring the second quarter of 2023—
Axonics, Inc. (Axonics)
“In the fourth quarter of 2024, we completed the acquisition of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction.” 10-K for 2024
acquisitionIn the fourth quarter of 2024—
Silk Road Medical, Inc. (Silk Road Medical)
“In the third quarter of 2024, we completed our acquisition of Silk Road Medical, Inc. (Silk Road Medical), a publicly traded medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally-invasive procedure called transcarotid artery revascularization.” 10-K for 2024
acquisitionIn the third quarter of 2024—
endoluminal vacuum therapy portfolio of B. Braun Medical Inc.
“Operational net sales growth included organic net sales growth of 8.0 percent in 2024, and the positive impact of 100 basis points from our acquisition of Apollo and the divestiture of our pathology business in the second quarter of 2023, and our acquisition of the endoluminal vacuum therapy portfolio of Braun in the first quarter of 2024.” 10-K for 2024
acquisitionfirst quarter of 2024—
Acotec Scientific Holdings Limited (Acotec)
“In 2023, relevant acquisitions and divestitures included our majority stake investment in Acotec Scientific Holdings Limited (Acotec) and the acquisitions of Apollo Endosurgery, Inc. (Apollo) and Relievant Medsystems, Inc. (Relievant) during the first, second and fourth quarters of 2023, respectively, as well as the divestiture of our pathology business during the second quarter of 2023.” 10-K for 2024
acquisition——
Apollo Endosurgery, Inc. (Apollo)
“In 2023, relevant acquisitions and divestitures included our majority stake investment in Acotec Scientific Holdings Limited (Acotec) and the acquisitions of Apollo Endosurgery, Inc. (Apollo) and Relievant Medsystems, Inc. (Relievant) during the first, second and fourth quarters of 2023, respectively, as well as the divestiture of our pathology business during the second quarter of 2023.” 10-K for 2024
acquisition——
Relievant Medsystems, Inc. (Relievant)
“Operational net sales growth included organic net sales growth of 2.7 percent in 2024, and the positive impact of 1,100 basis points from our acquisition of Relievant in the fourth quarter of 2023.” 10-K for 2024
acquisitionfourth quarter of 2023—
Cryterion Medical, Inc. (Cryterion)
“The impairment charges recorded in 2024 were primarily associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively.” 10-K for 2024
acquisition——
Devoro Medical, Inc. (Devoro)
“The impairment charges recorded in 2024 were primarily associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively.” 10-K for 2024
acquisition——
Bolt Medical, Inc.
“In the second quarter of 2025, we completed our acquisition of the remaining shares of Bolt Medical, Inc. (Bolt Medical), the developer of an intravascular lithotripsy advanced laser-based platform for the treatment of coronary and peripheral artery disease.” 10-K for 2025
acquisitionIn the second quarter of 2025—
SoniVie Ltd.
“In addition, we completed the acquisition of the remaining shares of SoniVie Ltd. (SoniVie), a privately held medical device company that has developed the TIVUS™ Intravascular Ultrasound System.” 10-K for 2025
acquisition——
Penumbra, Inc.
“The definitive agreement, entered into on January 15, 2026, to acquire Penumbra, for approximately $14.500 billion, which is expected to close during 2026, subject to customary closing conditions.” 10-K for 2025
agreed acquisitionJanuary 15, 2026approximately $14.500 billion
Nalu Medical, Inc.
“On January 27, 2026, we completed our acquisition of 100 percent of Nalu Medical, Inc. (Nalu Medical), a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain.” 10-K for 2025
acquisitionJanuary 27, 2026—
Reported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Cash received from selling businessesGoodwill from acquisitions
2016-12-31$408 million—$208 million
2017-12-31$560 million—$308 million
2018-12-31$1.45 billion$0$942 million
2019-12-31$4.38 billion$90 million$2.22 billion
2020-12-31$3 million$15 million—
2021-12-31$2.26 billion$826 million$2.06 billion
2022-12-31$1.54 billion$5 million$1.03 billion
2023-12-31$1.81 billion$0$1.45 billion
2024-12-31$4.64 billion$0$2.79 billion
2025-12-31$1.59 billion—$1.06 billion

Deal filings since 2016

Who are Boston Scientific's competitors?

Who Boston Scientific names

Boston Scientific’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.

Who names Boston Scientific

Companies whose own annual reports name Boston Scientific as a competitor.

  1. Abiomed · 2022

    “In addition, there are a number of companies, including Cardiovascular Systems Inc., Abbott Laboratories, Medtronic, Edwards Lifesciences, Boston Scientific, LivaNova, Terumo Heart, Teleflex, Getinge (Maquet Cardiovascular) and several early-stage companies, that are developing medical devices that provide circulatory support and oxygenation, including implantable left ventricular assist devices, miniaturized rotary ventricular assist devices and cardiopulmonary bypass devices that directly and indirectly compete with our products.” 10-K for 2022
  2. Cantel Medical · 2020

    “On a product basis, our principal competitors are Steris, Olympus, Boston Scientific, ASP (a division of Fortiv), Metrex, Ruhof, Ecolab, ERBE, Getinge, SteelCo and Wassenburg.” 10-K for 2020
  3. Globus Medical · 2025

    “Alphatec Holdings, Orthofix, Integra LifeSciences , ZimVie, VB Spine, Boston Scientific and other smaller public and private companies are also competitors of ours.” 10-K for 2025
  4. Haemonetics · 2026

    “Competitors such as Abbott Laboratories, Boston Scientific, and Philips pose challenges and opportunities in the coronary physiology segment, each offering their own technologies and solutions.” 10-K for 2026
  5. Merit Medical Systems names it as “Boston Scientific Corporation” · 2025

    “Our primary competitors in our peripheral intervention market are Teleflex Incorporated (“Teleflex”), Cook Medical Incorporated (“Cook Medical”), Medtronic plc (“Medtronic”), Boston Scientific Corporation (“Boston Scientific”), and Becton, Dickinson and Company (“BD”).” 10-K for 2025
  6. Penumbra · 2025

    “Our most notable competitors are Boston Scientific, Medtronic, Stryker (now including Inari Medical), Terumo and several private companies.” 10-K for 2025
  7. Steris · 2026

    “On a product basis, competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron and Wassenburg.” 10-K for 2026
  8. Varian Medical Systems names it as “Boston Scientific Corporation” · 2020

    “Our primary competitors include: Boston Scientific Corporation; Cook Medical LLC; Medtronic plc; Merit Medical Systems, Inc.; Terumo Medical Corporation; AngioDynamics, Inc.; MedWaves, Inc.; and Johnson & Johnson.” 10-K for 2020

What are Boston Scientific's subsidiaries?

Subsidiaries it lists

SubsidiaryJurisdiction
Ablacon GmbHGermany
Ablacon SA, en liquidationSwitzerland
Acotec Scientific Holdings LimitedCayman Islands
Acurate Industria e Comercio Ltda.Brazil
American Medical Systems Europe B.V.The Netherlands
Anchors (HZ) Medical Technology Co., Ltd.China
Anrei Medical Device (Hangzhou) Co., Ltd.China
Anrei Medical Device (Tianjin) Co., Ltd.China
Apollo Endosurgery UK LtdEngland
Apollo Endosurgery US, Inc.Delaware
Apollo Endosurgery, Inc.Delaware
Axonics, Inc.Delaware
Axonics Modulation Technologies Australia Pty LtdAustralia
Axonics Modulation Technologies, U.K. LimitedEngland
Axonics Women’s Health LimitedEngland
Baylis Medical Company Inc.Canada
Baylis Medical USA Inc.Delaware
Biocompatibles UK LimitedEngland
Biocompatibles, Inc.Delaware
Bolt Medical, Inc.Delaware
Boston Scientific (Malaysia) Sdn. Bhd.Malaysia
Boston Scientific (South Africa) Proprietary LimitedSouth Africa
Boston Scientific (Thailand) Ltd.Thailand
Boston Scientific AGSwitzerland
Boston Scientific Argentina S.A.Argentina
Boston Scientific Asia Pacific Pte. Ltd.Singapore
Boston Scientific Benelux NVBelgium
Boston Scientific Cardiac Diagnostic Services, LLCDelaware
Boston Scientific Cardiac Diagnostic Technologies, Inc.Delaware
Boston Scientific Cardiac Diagnostics, Inc.Delaware
Boston Scientific Ceska republika s.r.o.Czech Republic
Boston Scientific Chile SpAChile
Boston Scientific Clonmel Limited, in liquidationIreland
Boston Scientific Colombia LimitadaColombia
Boston Scientific Comercial de Costa Rica BSCR, S.R.L.Costa Rica
Boston Scientific de Costa Rica S.R.L.Costa Rica
Boston Scientific de Mexico, S.A. de C.V.Mexico
Boston Scientific del Caribe, Inc.Puerto Rico
Boston Scientific do Brasil Ltda.Brazil
Boston Scientific Egypt LLCEgypt
Boston Scientific Far East B.V.The Netherlands
Boston Scientific Gesellschaft m.b.H.Austria
Boston Scientific Group LimitedIreland
Boston Scientific Gulf for TradingSaudi Arabia
Boston Scientific Healthcare Technology (Shanghai) Co., Ltd.China
Boston Scientific Hellas S.A.Greece
Boston Scientific Holding One B.V.The Netherlands
Boston Scientific Holding Two B.V.The Netherlands
Boston Scientific Hong Kong LimitedHong Kong
Boston Scientific Iberica, S.A.Spain
Boston Scientific India Private LimitedIndia
Boston Scientific International B.V.The Netherlands
Boston Scientific International Distribution FZEUAE
Boston Scientific International Finance LimitedIreland
Boston Scientific International LLCDelaware
Boston Scientific International S.A.France
Boston Scientific International Sdn. Bhd.Malaysia
Boston Scientific Israel Ltd.Israel
Boston Scientific Japan K.K.Japan
Boston Scientific Korea Co., Ltd.Korea
Boston Scientific Korea Holding Co., Ltd.Korea
Boston Scientific LimitedEngland
Boston Scientific LimitedIreland
Boston Scientific LLCRussian Federation
Boston Scientific Ltd./Boston Scientifique Ltee.Canada
Boston Scientific Medical Device LimitedIreland
Boston Scientific Medical Device (Malaysia) Sdn. Bhd.Malaysia
Boston Scientific Medical Technology (Shanghai) Co., Ltd.China
Boston Scientific Medizintechnik GmbHGermany
Boston Scientific Middle East FZ-LLCUAE
Boston Scientific Middle East SAL (Offshore)Lebanon
Boston Scientific Nederland B.V.The Netherlands
Boston Scientific Neuromodulation CorporationDelaware
Boston Scientific New Zealand LimitedNew Zealand
Boston Scientific Nordic ABSweden
Boston Scientific Pakistan (Private) LimitedPakistan
Boston Scientific Peru S.A.C.Peru
Boston Scientific Philippines, Inc.Philippines
Boston Scientific Polska Sp. z o.o.Poland
Boston Scientific Portugal - Dispositivos Medicos, LdaPortugal
Boston Scientific Pty LtdAustralia
Boston Scientific Puerto Rico LLCPuerto Rico
Boston Scientific Regional HeadquartersSaudi Arabia
Boston Scientific Romania S.R.L.Romania
Boston Scientific S.A.S.France
Boston Scientific S.p.A.Italy
Boston Scientific Scimed, Inc.Minnesota
Boston Scientific Technology & Engineering Services Private LimitedIndia
Boston Scientific TIP Gerecleri Limited SirketiTurkey
Boston Scientific Vietnam Company LimitedVietnam
BSC International Medical Trading (Shanghai) Co., Ltd.China
BSC Medical Device Technology (Shanghai) Co., Ltd.China
BTG IM Holdings Ltd., in liquidationIsrael
BTG International Canada Inc.Canada
BTG International LimitedEngland
BTG LimitedEngland
Cardiac Pacemakers, Inc.Minnesota
CarioICE LLCDelaware
Chess Medical Inc.Canada
Corbin Clinical Resources, Inc.Delaware
Corbin Clinical Resources, LLCMaryland
Cortex, Inc.Delaware
DeVoro Medical Inc.Delaware
eCardio Sequoia Blocker Corp.Delaware
Electron Acquisition CorporationDelaware
EndoChoice, Inc.Delaware
EP Technologies, Inc.Delaware
Falcon Merger Sub, Inc.Delaware
Farapulse, Inc.Delaware
Galil Medical Inc.Delaware
Galil Medical Ltd., in liquidationIsrael
Golden Woods Services, LLCTexas
Guidant Delaware Holding CorporationDelaware
Guidant Europe NVBelgium
Iceberg Merger Sub, Inc.Delaware
Intera Oncology Inc.Delaware
JND Therapeutics, Inc.Delaware
Laguna Holdco Ltd.Israel
Lumenis (HK) LimitedHong Kong
Lumenis India Private LimitedIndia
Lumenis Ltd.Israel
Nalu Medical, Inc.Delaware
Notebook Merger Sub, Ltd.Delaware
NXT Merger Corp.Delaware
Obsidio, Inc.Delaware
Pinehurst Merger Sub, Inc.Delaware
Provensis LimitedEngland
PT Boston Scientific IndonesiaIndonesia
Relievant Medsystems, Inc.Delaware
RMI Acquisition Corp.California
Shanghai Anzhiqiao Medical Technology Co., Ltd.China
Silk Road Medical, Inc.Delaware
SNS Merger Corp.Delaware
SoniVie Ltd.Israel
SoniVie, Inc.Delaware
SoundCath, Inc.Delaware
Special K Merger Corp.Delaware
Stream Enterprises LLCDelaware
Symetis SA, en liquidationSwitzerland
Target Therapeutics, Inc.Delaware
VBio Merger Subsidiary, Inc.Delaware
VTC Merger Subsidiary, Inc.Delaware
Zuma Investment Pty LtdAustralia
165Bio Inc.Delaware
34 Biomedical Merger Corp.Delaware
9357-1867 Quebec Inc., d/b/a Cryterion Medical EnterpriseCanada

From Exhibit 21 of the 10-K for 2025. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.

Layoffs, acquisitions, competitors and subsidiaries are read from Boston Scientific’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023), as of 2026-02-17.

The full data sheet · Data Plan

Everything behind these findings, ready for your board deck.

  • Market reaction to disclosed decisions: 69 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (44 with market data).
  • Economic context: 7 measures for the United States, every year since 2016, from the official sources.
  • Peer comparison: against 264 companies of its size in its sector.
  • Financial results: ten years of revenue, operating and net income, and every annual report, linked.
  • Methods and sources, so each number can be checked and cited.

The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.

Tools to try

More from Stratrix

The Business Model Wizard

Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.

Free · about twelve minutesBuild your Model Thesis →

Weekly email

Stratonomics, every Tuesday

One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.

We'll email you a link to confirm. Unsubscribe anytime. Privacy policy.